Prelude Therapeutics (PRLD)
(Delayed Data from NSDQ)
$3.73 USD
-0.34 (-8.35%)
Updated May 10, 2024 04:00 PM ET
After-Market: $3.71 -0.02 (-0.54%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth A Momentum B VGM
Industry / Sector Report
Industry : Medical - Drugs
Zacks Industry Rank
Top 37% (94 out of 251)Zacks Sector Rank
Top 25% (4 out of 16)Recommendations and Estimates
Company | Industry | SP500 | |
---|---|---|---|
Average Recommendation (1=Buy, 5=Sell) | 2.34 | 1.52 | 9.99 |
Current Quarter Estimate | -0.46 | -2.04 | 57.00 |
Year Ago Quarter Estimate | -0.54 | -0.59 | 52.54 |
Next Quarter Estimate | -0.46 | -2.00 | 61.00 |
Next Year Estimate | -1.86 | 6.92 | 270.00 |
Growth Rates
Company | Industry | SP500 | |
---|---|---|---|
This Year | 8.91 | 11.80 | 15.67 |
Next Year | -1.09 | 15.40 | 9.31 |
Last 5 Years | NA | 4.90 | 8.10 |
Next 5 Years | NA | 22.20 | NA |
Financials
Company | Industry | |
---|---|---|
Price/Earnings (TTM) | NA | -5.88 |
Price/Book (MRQ) | 0.74 | 1.91 |
Price/Cash Flow (MRFY) | NA | 9.59 |
Dividend Yield | 0.00% | 0.00% |
Net Profit Margin (TTM) | NA | 0.82% |
Return on Equity (TTM) | -52.97% | -24.69% |
Debt to Equity (MRQ) | 0.00 | 0.04 |
MRQ = Most Recent Quarter
TTM = Trailing Twelve Months
MRFY = Most Recent Fiscal Year
Note: Company and S&P 500 ratios relating to share price calculated daily; all others calculated weekly or in accordance with company earnings announcement. Industry medians calculated weekly.